Larger trials such as EMPEROR-PRESERVED (5988 patients) and DELIVER (6263 patients) are the two largest trials to date evaluating the benefits of SGLT-2 inhibitors in patients with HF with LVEF >40% [20,21]. Here, SLC5A2 is linked to hydrops fetalis.